Similar articles

• Viral safety of clotting factor concentrates.

  Fricke WA, Lamb MA. Fricke WA, et al. Semin Thromb Hemost. 1993;19(1):54-61. doi: 10.1055/s-2007-994006. Semin Thromb Hemost. 1993. PMID: 8456324 Review.
• FDA perspective on and response to the risk of hepatitis A from blood products.

  Fricke W. Fricke W. Vox Sang. 1994;67 Suppl 4:16-8; discussion 24-6. Vox Sang. 1994. PMID: 7831864 Review.
• Viral safety and clotting factor concentrates.

  Laurian Y, Lusher JM, Kessler CM. Laurian Y, et al. Thromb Haemost. 1994 Oct;72(4):649. Thromb Haemost. 1994. PMID: 7878650 No abstract available.
• [Viral hepatitis following administration of the 4 coagulation-factors concentrate PPSB].

  Penn HJ. Penn HJ. Ned Tijdschr Geneeskd. 1979 Sep 1;123(35):1532-3. Ned Tijdschr Geneeskd. 1979. PMID: 492370 Dutch. No abstract available.
• Virus safety of pasteurized clotting factor concentrates.

  Kreuz W, Becker S, Auerswald G, Kurnick K, Kröniger A, Klarmann D. Kreuz W, et al. Semin Thromb Hemost. 2002 Apr;28 Suppl 1:57-62. doi: 10.1055/s-2002-30197. Semin Thromb Hemost. 2002. PMID: 12016580 Review. No abstract available.